

1 **Title:** Antibiotic prescribing patterns by age and sex in England: why we need to take this  
2 variation into account to evaluate antibiotic stewardship and AMR selection

3 *Naomi R Waterlow<sup>1,2</sup>, Tom Ashfield<sup>3</sup>, Gwenan M Knight<sup>1,2</sup>*

4 1 - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease  
5 Epidemiology, London School of Hygiene and Tropical Medicine, WC1E 7HT

6 2 - AMR Centre, London School of Hygiene and Tropical Medicine, WC1E 7HT

7 3 - The Signpost, Winchester, England

8

9

10

11

## 12 **Structured Abstract**

### 13 *Objectives*

14 The drivers of antimicrobial resistance (AMR) likely vary substantially by different  
15 demographics. However, few complete open national detailed data exist on how  
16 antibiotic use (ABU) varies by both age and sex.

### 17 *Methods*

18 Here, prescriptions of antibiotics from General Practices in England for 2015-2023  
19 disaggregated by 5-year age bands and sex were analysed at the national and Integrated  
20 Care Board (ICB) level. From a total of 249,578,795 prescriptions (across 9 years), 63%  
21 were given to women and the most prescribed were amoxicillin, nitrofurantoin and  
22 flucloxacillin sodium. Prescriptions per 100K population varied substantially across sex,  
23 age, geographical region, season, year, COVID-19 pandemic period and drug.

### 24 *Results*

25 Most antibiotics were prescribed more to women across most age bands (84% of  
26 antibiotics had more prescriptions to females across 50% of age bands). We show how  
27 this variation requires a more nuanced approach to comparing ABU across geographies  
28 and highlight that AWaRe targets are not met uniformly (young men have a higher  
29 proportion of “Watch” antibiotic prescriptions). We also show the impact on ABU of  
30 time-sensitive interruptions, including differential age-targeted influenza vaccination,  
31 COVID-19 restrictions and a shortage of amoxicillin combined with a Streptococcus A  
32 outbreak. Comparing to open access AMR data (MRSA in bloodstream infections)  
33 highlights the complexity of the link between ABU and AMR.

### 34 *Conclusions*

35 These detailed differences in ABU across England suggest that there should be large  
36 variation in AMR burden by age and sex, which now need to be quantified with detailed  
37 open access AMR data for a better intervention design.

## 38 Introduction

39

40 The global public health priority that is antimicrobial resistance (AMR) is driven by a  
41 population-specific combination of antibiotic selection and transmission. There are  
42 many global targets that focus on the reduction of antibacterial use (ABU). One such  
43 target already adopted by the WHO 13<sup>th</sup> General Programme of Work is to have at least  
44 60% of total antibiotic consumption within the Access group of AWaRe antibiotics <sup>1-3</sup>.  
45 More ambitiously, it has been proposed that 80% or more of oral antibiotic use could be  
46 Access <sup>2,4</sup>. To achieve such targets without affecting patient care, it will be key to  
47 produce nuanced information about ABU across different subpopulations.

48 Most antibiotics are given outside of hospital settings <sup>5,6</sup> and previous studies have  
49 suggested that primary care antibiotic use (and hence exposure) varies substantially by  
50 age and by sex. A systematic review of primary care prescribing in 2016 suggested that  
51 women in high income settings receive a significantly higher number of prescriptions,  
52 particularly in the 16 to 54 years age band <sup>7</sup>. This is supported by sub-national  
53 analyses<sup>8-10</sup> from the UK, for example approximately twice as many antibiotic  
54 prescriptions given to women in 2013-2015, and 70% of all prescriptions after excluding  
55 antibiotics used to treat urinary tract infections (UTIs) <sup>8</sup>. Antibiotic exposure rates are  
56 often “hockey-stick” shaped across age, with high levels in young children and an  
57 exponential increase with age <sup>7,11</sup>. This is likely to reflect that different age/sex sub-  
58 groups present with different rates of infections<sup>12</sup> and hence some level of appropriate  
59 prescription variation. For example women have higher rates of UTIs <sup>13</sup>.

60 Antibiotic use also varies geographically at national and sub-national levels <sup>14-16</sup>.

61 Identifying outliers once patient composition is accounted for, is vital for improving

62 antibiotic stewardship<sup>17,18</sup>. To do this, various measures have been proposed such as

63 the English STAR-PU <sup>19</sup> which uses different prescribing weights in different ages and

64 sexes. Issues with this metric include the lack of accounting of co-morbidities <sup>18</sup> and the

65 grouping of all antibiotics together masking variation in antibiotic use due to patient or

66 GP-related factors <sup>20</sup>, although variation in prescribing may be decreasing over time <sup>21</sup>.

67 To reduce ABU many age-specific interventions could be considered, for example

68 vaccination programmes are postulated to reduce both unnecessary and necessary

69 antibiotic use <sup>22,23</sup>. Evidence that such a reduction in antibiotic exposure leads to

70 reduced resistance is mixed<sup>24</sup>, but age- and sex-disaggregated ABU could be used to

71 reveal where there is a link between vaccination and ABU, as well as ABU and

72 resistance rates. However, few ecological open access ABU or AMR data exist

73 disaggregated by both age and sex. In one of the only detailed age and sex analyses, we

74 have previously shown that AMR prevalence in bloodstream infections in Europe varies

75 substantially by age, sex and bacteria-antibiotic combination <sup>25</sup>.

76

77 Here we use 9 years of open access national data on antibiotic prescriptions from

78 primary care in England available at an unprecedented level of both age and sex

79 disaggregation to reveal the variation in ABU. We test assumptions about antibiotic

80 weightings used for identifying prescribing outliers, conduct a nuanced analysis of

81 AWaRe targets, generate estimates of the impact on ABU of age-based influenza

82 vaccination, and explore the link between ABU and AMR. The patterns we find show the

- 83 importance of such nuanced data and emphasise the need for more disaggregated AMR
- 84 data.

## 85 **Materials & Methods**

86

87 The number of primary care antibiotic prescriptions by 23 age bands and 3 genders in

88 England & Wales was received through two freedom of information requests (FOI-

89 01671, FOI-01975)<sup>26</sup> to the NHS Business Service Authority (NHSBSA) Information

90 Services Data Warehouse containing information from the NHSBSA Prescription

91 Services. The first FOI contains data at General Practice (GP) and Integrated Care Board

92 (ICB) level for England and some of Wales. The second is total national English data

93 only.

94

95 This data covers the 9 year period of April 2015 to December 2023 inclusive, by month,

96 and includes all medicines from the British National Formulary (BNF) section 5.1:

97 Antibacterial drugs<sup>27</sup>. Datapoints relating to fewer than 5 items prescribed were

98 redacted by NHSBSA for privacy reasons. The 23 age bands were “0-1”, “2-5” and then

99 5yr age bands up to “105+”. The three gender classes included were “Male”, “Female”

100 and “Indeterminate” (where information does not confirm either Male or Female). We

101 used number of items prescribed in our analysis, so as to avoid double-counting of

102 patients<sup>26</sup>.

103

104 Of total prescriptions in the dataset, 3.3% were prescribed to a patient of unknown

105 gender or age band. We excluded these prescriptions from our analysis, although note

106 that the frequency varied with time, with fewer unknowns over time (Appendix 1 section

107 2). We also excluded prescriptions given to individuals of “Indeterminate” gender, due

108 to the small numbers (6247 items, 0.0024%) and the antibiotics for which there were

109 less than an average of 10 prescriptions per year (22 antibiotics, Appendix 1 section 3).  
110 For our main analysis, we assumed all redacted numbers of items had a value 1 (from a  
111 possible 1,2,3 or 4), and run sensitivity analyses on this number (Appendix 1 Section 7).  
112  
113 Population sizes by age were obtained from the Office for National Statistics (ONS) and  
114 mid-year estimates were used for each calendar year<sup>28,29</sup> (Appendix 1 Section 4). We  
115 only included prescriptions for England in the analysis, and only those for 2023 were  
116 used for sub-national analyses, due to changes in the definitions of the ICBs. Data from  
117 NHSBSA provides “Gender”, but most other sources use “Sex”. We have assumed that  
118 we can match these two in this analysis.  
119  
120 We calculated an updated STAR-PU weighting of antibiotic prescriptions per age band  
121 and sex, with smaller age bands<sup>19</sup>. The updated comparison metric (UCM) weightings  
122 were calculated using females aged 66-70 as baseline (a subset of the STAR-PU 65-74  
123 female baseline). Our UCM weightings were then applied to the ICBs in 2023, using the  
124 same STAR-PU principles: the new UCM weightings were multiplied by the relevant  
125 populations in each ICB, and the total prescriptions per UCM-population were used to  
126 compare ICBs. In addition, drug family-based weightings were calculated using the  
127 same methodology (“UCM-family”), but prescriptions from each drug family were used.  
128 For children aged up to 16 (the only age groups where there were sometimes no  
129 prescriptions) a value of 0.01 was used if there were no data in that age band, and limits  
130 were set of 0.01 to 100.  
131



132 Drugs were classified into the AWaRe categories using a World Health Organisation  
133 reference table<sup>30</sup>. Where drug names were not identical, these were manually matched  
134 (Appendix 1 section 1).

135

136 Age bands covered by influenza vaccination were extracted from the annual UKHSA  
137 reports<sup>31</sup>, and these were compared to prescriptions of antibiotics used in respiratory  
138 tract infections (RTIs)(defined as all drugs in the BNF categories “cephalosporins and  
139 other beta-lactams” and “penicillins”), excluding amoxicillin. Amoxicillin was excluded  
140 due to the very large number of prescriptions, and it’s use in many varieties of infection  
141<sup>32</sup>. The influenza season was defined as 1st of October to 30th March inclusive. The  
142 number of prescriptions given to patients in age bands that matched closely to the  
143 vaccination groups was calculated where possible (0-1, 2-5, 5-10, 11-15, 50-65, 65+).

144

145 We extracted the only publicly available data on AMR infection split by age and sex. This  
146 was for *Staphylococcus aureus* bloodstream infection data from UKHSA<sup>33</sup>. The  
147 proportion of these BSIs due to *S. aureus* that were methicillin-resistant (MRSA) were  
148 compared to prescriptions of antibiotics in the BNF categories “cephalosporins and  
149 other beta-lactams” and “penicillins”.

150

151 Data collection and transmission rates were altered during the years of SARS-CoV-2  
152 circulation and lockdowns, which we classified to be from March 2020 to June 2022  
153 inclusive for England.

154

155 All code is available on github ([https://github.com/NaomiWaterlow/prescription\\_foi](https://github.com/NaomiWaterlow/prescription_foi))

156 and was conducted in R<sup>34</sup>.

157

158 *Sensitivity analysis*

159 The main issue to explore in the data was the uncertainty in the redacted small numbers

160 (“\*”) when the number of prescriptions was between 1-4. In sensitivity analysis we

161 explored changing our default value of 1 to 4 for (a) everyone, (b) males only and (c)

162 children only (< 20yos).

163

## 164 **Results**

165

### 166 Prescription data

167 Over the 9-year period April 2015 to December 2023, 249,578,795 prescriptions of  
168 antibiotics were given in England. For the complete years (2016-2023), the average was  
169 0.48 (range of 0.43, 0.52) prescriptions per person per year. The most frequently  
170 prescribed drugs were amoxicillin, nitrofurantoin and Flucloxacillin sodium (Table 1).  
171 63% (63%, 64%) of drugs were prescribed to females, with 0.60 (0.54, 0.65) per person  
172 per year versus 0.36 (0.31, 0.40) in men. 13% (10%, 15%) of prescriptions were given to  
173 those <16yo, and 35% (33%, 37%) to those over 65yo. The highest overall prescription  
174 rate in both sexes was in the 86yo+ band (Appendix 1 section 5). COVID-19 mostly  
175 affected prescribing in those aged < 16yos (Appendix 1 section 5), mostly returning to  
176 pre-COVID-19 levels in the Spring of 2021.

177

178 The top 20 prescribed antibiotics, totalling 98% of prescriptions, (Table 1) had annual  
179 prescription totals varying from 74,159 to over 6.5 million prescriptions, with most being  
180 prescribed more commonly to females (17/20) and most often in December (9/20) or  
181 January (5/20). Those prescribed more to men were ciprofloxacin, co-trimoxazole and  
182 rifamixin. Just over half of the top 20 prescribed antibiotics had fewer prescriptions in  
183 2023 than 2016 (11/20), with 61% of antibiotic having at least a 10% reduction in  
184 prescriptions between 2019 and 2023, although some had sex-based time variation  
185 (e.g. ofloxacin, Fig 1B). Most of the top 20 antibiotics (15/20) had the highest rates in  
186 older ages (>55yos) in 2023.

Antibiotic	Total	Mean (annual)	% to females	Top month	Total in			Top age band (2023)	
					2016	2019	2023	Females	Males
Amoxicillin	53,415,335	6,676,917	58	12	8,130,012	6,673,263	7,311,226	0-1,2-5,86+	0-1,2-5,86+
Nitrofurantoin	27,953,870	3,494,234	83	10	2,358,297	3,740,424	3,808,622	76-80,81-85,86+	76-80,81-85,86+
Flucloxacillin sodium	26,940,364	3,367,546	55	7	3,488,057	3,270,904	3,384,802	76-80,81-85,86+	76-80,81-85,86+
Doxycycline hyclate	22,868,632	2,858,579	60	12	2,415,657	2,772,514	3,804,564	76-80,81-85,86+	76-80,81-85,86+
Penicillin V	15,557,160	1,944,645	59	12	1,892,172	1,841,679	2,447,555	2-5,6-10,16-20,	0-1,2-5,6-10
Trimethoprim	14,439,590	1,804,949	75	1	3,087,875	1,488,922	1,428,569	76-80,81-85,86+	76-80,81-85,86+
Clarithromycin	14,417,677	1,802,210	63	1	2,077,261	1,845,315	1,743,846	76-80,81-85,86+	76-80,81-85,86+
Co-amoxiclav	9,181,476	1,147,684	60	1	1,304,696	1,094,885	1,092,620	76-80,81-85,86+	76-80,81-85,86+
Lymecycline	7,938,074	992,259	58	3	1,054,631	1,032,182	861,423	11-15,16-20,21-25	11-15,16-20,21-25
Cefalexin	5,910,292	738,786	80	12	748,696	668,339	816,579	76-80,81-85,86+	76-80,81-85,86+
Azithromycin	5,877,890	734,736	57	12	612,414	748,885	805,700	71-75,76-80,81-85	76-80,81-85,86+
Metronidazole	4,156,192	519,524	78	3	599,382	520,332	474,629	21-25,26-30,31-35	76-80,81-85,86+
Ciprofloxacin	3,564,433	445,554	48	1	532,816	445,243	355,804	76-80,81-85,86+	76-80,81-85,86+
Erythromycin	3,397,046	424,631	66	1	709,522	394,861	286,163	76-80,81-85,86+	76-80,81-85,86+
Oxytetracycline	2,432,724	304,090	51	3	463,514	310,851	178,452	61-65,66-70,76-80	71-75,76-80,81-85
Piv. hydrochloride	1,790,378	223,797	79	10	108,361	223,030	301,447	76-80,81-85,86+	76-80,81-85,86+
Ery. ethylsuccinate	1,576,325	197,041	50	12	341,227	171,870	164,552	0-1,2-5,6-10	0-1,2-5,6-10
Co-trimoxazole	1,417,031	177,129	44	12	129,051	173,722	228,051	66-70,76-80,81-85	76-80,81-85,86+
Meth. Hippurate	1,060,060	132,508	80	12	40,789	82,081	319,013	76-80,81-85,86+	76-80,81-85,86+
Rifaximin	593,273	74,159	41	12	33,589	71,036	109,205	56-60,61-65,66-70	56-60,61-65,66-70

188

Table 1: Summary data on number of prescriptions for the 20 most prescribed antibiotics (see Appendix 1 section 6 for all antibiotics) across the complete years of the data (2016-

189

2023) unless otherwise indicated. Red shading indicates more prescriptions are to females and "Top" month is the month with the most prescriptions of this antibiotic (1 = January),

190

when summing across the whole dataset. "Top age band (2023)" is the age band in 2023 with the highest prescription rate per 100k. Light green shading indicates relatively more

191

prescriptions to younger individuals vs top age bands all being 55yo or more (Ery. is Erythromycin. Co-amoxiclav is amoxicillin and clavulanic acid, Co-trimoxazole is trimethoprim

192


and sulfamethoxazole. Piv. = Pivmecillinam. Meth. = Methenamine.)

193 Twenty-eight antibiotics (38%) show an annual seasonal pattern (Fig 1A, Appendix 2) in  
194 prescriptions (pre-COVID-19), defined as having at least two months where  
195 prescriptions were 20% higher than the average number of prescriptions, averaged over  
196 years. These seasonal antibiotics, all had a decrease in prescriptions during the COVID-  
197 19- period, followed by a spike in late 2022 (Appendix 2) correlating with a  
198 Streptococcus A outbreak and amoxicillin shortage<sup>35</sup>.

199

200 For most age bands higher levels of prescription in females compared to males (Fig 1C),  
201 were observed (84% / 54% / 24% of antibiotics had more prescriptions to females in at  
202 least 50% / 75% / 90% of age bands respectively). Notable exceptions with higher  
203 prescriptions to males are quinolones, isoniazid and minocycline hydrochloride. For  
204 some ages the sex that receives the most prescriptions changes with age (e.g.  
205 colistimethate sodium, azithromycin and rifampicin have higher prescriptions in males  
206 in children, higher prescription rates in females in adults (Fig 1C)).

207



208

209 *Figure 1: Variation in antibiotic prescribing by age and sex with examples and overall comparison A/B). Example*  
 210 *prescription rate per 100'000 population for clarithromycin and ofloxacin respectively. Colours indicate age bands,*  
 211 *facets indicate sex. Grey shading indicates years of COVID-19 interventions. See Appendix 2 for all antibiotics. C)*  
 212 *Relative prescription rate by sex for prescribed medicines in 2023. Colours represents the log of the ratio, with blue*  
 213 *indicating higher prescriptions in women, and green indicating higher prescriptions in men. Drugs are ordered by BNF*  
 214 *classification, where the acronyms are: Clindamycin and lincomycin = "C&L", Cephalosporins and other beta-*  
 215 *lactams = "Ceph's", Antileprotic drugs = "Lep", Metronidazole, tinidazole and ornidazole = "MTO", Sulphonamides and*  
 216 *trimethoprim= "S&T", Antituberculosis drugs = "TB", Urinary-tract infections = "UTIs".*


217

218 *Antibiotic usage metric*

219 We created an updated comparison metric (UCM), with smaller age bands than STAR-  
 220 PU (Figure 2B). This resulted in more extreme values across age bands, ranging from  
 221 0.19 to 2 in our UCM, compared to a range of 0.2 – 1.3 in the 2013 STAR-PU with  
 222 particularly higher values in older males (Figure 2A vs B). Values by BNF drug value  
 223 varied considerably by age and sex ("UCM-family", Appendix 1 section 7).

224


225 The new-UCM ranking of ICBs (first column Fig 2C, lines in Fig 2D), changed  
 226 substantially when applying the UCM-family (Fig 2C, points in Figure 2D). For example,  
 227 ICB QRL ranks as a high prescriber with the new-UCM (6<sup>th</sup> overall, Fig 2C, red in  
 228 Fig2C&D) but a low prescriber of quinolones (38<sup>th</sup> overall, Appendix 1 section 9). The  
 229 range in UCM-family ranking decreased with more prescriptions (Fig 2D).  
 230



231  
 232 *Figure 2: A) 2013 STAR-PU values using England data. B) Updated Comparison Metric (UCM) using 2023 English data*  
 233 *and more disaggregated age bands. Blue = high value, green = low value, centred around the baseline: females, 66-70*  
 234 *(white). C) Ranking of UCMs across English ICBs, grouped by colour into quarters: rank 1-10 (1), 11-20 (2), 21-30 (3)*  
 235 *and 30-42 (4). The “Overall” column shows the ranking of ICBs using our UCM, and the other columns by UCM-family.*  
 236 *Acronyms: Clindamycin and lincomycin = “C&L”, Cephalosporins and other beta-lactams = “Ceph’s”, Antileprotic*  
 237 *drugs = “Lep”, Metronidazole, tinidazole and ornidazole = “MTO”, Sulphonamides and trimethoprim= “S&T”,*  
 238 *Antituberculosis drugs = “TB”, Urinary-tract infections = “UTIs”. D) Normalised prescriptions per English ICB and*  
 239 *antibiotic (facet) for overall UCM (lines, same on each facet) and UCM-families (dots). In C) and D) the same three*  
 240 *ICBs are highlighted with colour (blue, yellow and pink). n indicates the total number of prescriptions across all ICBs.*

241  
 242 *Antibiotic consumption targets*

243 The WHO 60% “Access” prescribing target has been reached in England: 84% of primary  
 244 care prescriptions were “Access” in 2023. However, the more ambitious 80% level is not  
 245 being met in males ages 11-20, largely driven by a spike in prescriptions for lymecycline  
 246 (Figure 3B), commonly prescribed for Acne<sup>36</sup>. The main Reserve drug prescribed by GPs  
 247 in 2023 was colisitmethate sodium, which must be given by injection or as a nebuliser  
 248 as it is not given orally<sup>37</sup>, likely under the direction of tertiary care, particularly for Cystic  
 249 Fibrosis patients<sup>38,39</sup>. The percentage of antibiotics that were “Access” varied across  
 250 ICBs by between 5.3% (females, aged 6-10) to 13.4% (males, aged 16-20) (Appendix 1  
 251 Section 10).




252  
 253  
 254 *Figure 3: A) Percentage of total prescriptions in each of the AWARe categories (row), by age band, sex (column) and*  
 255 *year (colour). Dashed horizontal lines represent targets of 60% and 80% in the Access category, and dotted vertical*  
 256 *lines are included for comparison across graphs. Note the difference in y-axis ranges. B) Total prescriptions in 2023 by*  
 257 *AWARe categories (row), age band and sex (columns). Key contributing drugs are highlighted by colour and vertical*  
 258 *dotted lines are included for comparison across graphs.*

259 *Influenza vaccination*



260 Comparing the relative rate of prescriptions commonly given for (suspected) RTIs before  
 261 and after influenza vaccination programmes (Figure 4A) shows no clear impact. For  
 262 example, compared to ages 15-50, RTI relative prescription rates declined by just under  
 263 5% in age band 6-10 following introduction of vaccination in 7-8yos (Figure 4A&B).  
 264 However, in this same period the prescriptions in age bands 0-1 decreased by over 10%.  
 265 There was an increase in relative prescriptions in all ages except older adults when  
 266 vaccination was introduced in 4-5yos & 8-9yos. Vaccination of 50-65yos would likely  
 267 have the largest impact (more people), but is hard to interpret, as this occurred during  
 268 the COVID-19 years. No decrease in prescriptions in this age band compared to the  
 269 other age bands was identified (Fig 4A).



270

271

272 *Figure 4: A) Age band specific prescription rates of RTI antibiotics (penicillins, cephalosporins and other beta-*  
 273 *lactams) relative to the rate in age band 15-50. Amoxicillin was excluded (see methods). The influenza season was*  
 274 *defined as 1<sup>st</sup> of October to 30<sup>th</sup> March inclusive. Vertical lines indicate the year the introduction of vaccination in the*  
 275 *labelled age band, and the COVID-19 years are shaded grey. B) Proportional change in the number of RTI*  
 276 *prescriptions (excluding amoxicillin) from the influenza season of the previous year, by age band. Vertical lines*

277 *indicate the introduction of vaccinations in the named age bands C) Prescription rate of beta-lactam antibiotics (top*  
278 *row) and proportion of BSI due to resistant S. aureus (over all S. aureus BSI) for similar age bands (columns) .*

279

280 *Impact on antimicrobial resistance (AMR)*

281 There was a lack of a clear link between prescribing and resistance rates by age and sex  
282 for *S. aureus* (Figure 4C). All age bands except ages 0-1 see higher prescriptions of beta-  
283 lactam antibiotics (those to which MRSA are resistant) in females, yet the proportion of  
284 BSIs due to MRSA is higher in males 45yo and over, and varies over time in 1-44yo. As  
285 opposed to prescriptions, a higher proportion of BSIs were due to MRSA in females in  
286 age band <1 over time.

287

288 *Sensitivity analyses*

289 The majority of age bands across drugs show higher levels of prescription in females  
290 compared to males in all sensitivity analysis. When the hidden low prescription  
291 numbers (\*s) were all set to the maximum possible value (4 instead of 1, equating to  
292 0.13% instead of 0.033% of all prescriptions), 85% / 55% / 27% of antibiotics had more  
293 prescriptions to females in at least 50% / 75% / 90% of age bands respectively. The  
294 sensitivity analysis with the higher value (4) in males only or children only had highly  
295 similar levels of 78% / 55% / 18% and 85% / 55% / 24% respectively (Appendix 1 section  
296 7).

## 297 **Discussion**

298

299 We report here, for the first time, national data on all antibiotic prescriptions in primary  
300 care in England disaggregated by both 5yr age bands and sex. This unprecedented level  
301 of detail highlights huge variation and will be vital in bringing a more nuanced approach  
302 to AMR control.

303

304 Whilst most antibiotics (15/20 of most prescribed antibiotics) had higher prescription  
305 rates in older ages (55yo+), a substantial proportion had higher prescription rates in  
306 children or younger adults. Matching previous reporting<sup>7-10</sup>, women were prescribed  
307 more antibiotics, but this pattern was not uniform across age bands and the patterns  
308 seen would have been hidden if using only three age groupings. Higher prescribing in  
309 women is likely linked to both infection syndrome variation and to behavioural  
310 differences in consultation rates<sup>8,40-43</sup>. We saw clear syndrome-linked prescribing:  
311 higher levels of UTI prescribing (nitrofurantoin and trimethoprim) in women and higher  
312 levels of prostate or gonorrhoea infection linked prescribing (ofloxacin) in men.  
313 Quantifying this age and sex variation provides a baseline for intervention targeting and  
314 may help assess prescription appropriateness.

315

316 Most antibiotics (~60%) did not have a seasonal pattern of exposure. Those that did had  
317 a lower prescribing rate during COVID-19, likely reflecting that antibiotics prescribed  
318 seasonally are given for infections that are dependent on seasonal changes in  
319 transmission (schools / time indoors), or linked to other infections (e.g. respiratory  
320 viruses<sup>44,45</sup>). Supporting this theory is the rapid increase in prescribing in late 2022

321 which coincided with a *Streptococcus A* outbreak and a wide increase in prevalence of  
322 respiratory virus infections linked to “re-opening”<sup>46</sup>. How this could drive seasonality in  
323 AMR needs untangling. Other studies have found a similar decrease in prescribing  
324 during COVID-19 in primary care in sub-national data in the UK<sup>47 48</sup>, mostly driven by  
325 prescribing in children.

326

327 These data allow for more subtle analysis of prescribing outliers. We found that STAR-  
328 PU likely underestimates prescribing to older adults, especially males and that a metric  
329 split by antibiotic family would better identify outliers. This analysis strengthens the  
330 case for updated STAR-PU<sup>s</sup><sup>49</sup>.

331

332 England is exceeding the WHO “60% Access” targets for antibiotic use, and likely has  
333 been since 2018, like other European settings<sup>50</sup>. However, this data shows the utility of  
334 knowing the variation by detailed age bands and sex: males aged 11-20 had less than  
335 60% Access in 2015, rising to 70% in 2023 due to an increase in prescribing of the watch  
336 antibiotic lymecycline, likely for acne<sup>36</sup>. Whilst also spiking in females, due to the higher  
337 overall prescribing in women, their proportion Access remains above 70%.

338

339 Interventions to reduce antibiotic prescribing, including the Quality Premium, appear to  
340 be working in general in England, with most antibiotics (61%) having at least a 10%  
341 reduction in prescriptions between 2019 and 2023<sup>51,52</sup>. Disaggregating by age and sex  
342 reveals subgroups where changes in prescribing practice could be further targeted e.g.  
343 ofloxacin use has increased in men since 2016, potentially linked to rises in gonorrhoea  
344<sup>53</sup>. Interestingly, a large reduction in prescriptions is not evidently driven by more ages

345 being eligible for influenza vaccination: despite roughly 50% vaccine coverage we saw  
346 little prescription reduction in that ‘flu season in the age group vaccinated nor in linked  
347 age groups known to benefit from ‘flu vaccination of children (e.g. 65+ age band)<sup>54,55</sup>.  
348 These results are lower than those previously reported (e.g. 29% reduction in antibiotic  
349 prescribing in one systematic review<sup>22</sup>) potentially due to our grouping antibiotics  
350 together, using wider age bands (to match vaccine targets) and not considering  
351 influenza complexity (e.g. strain variation). The impact of influenza vaccinations may  
352 also be higher in other non-UK settings.

353

354 When considering AMR selection, we found no obvious link between the age and sex  
355 disaggregated exposures of beta-lactam antibiotics in primary care and higher MRSA  
356 prevalence in bloodstream infections (BSIs) in England. However, MRSA is often a  
357 hospital-associated pathogen<sup>56</sup>, and BSIs are usually treated in hospitals, hence a lack  
358 of a strong link might have been expected but not no link. More broadly, we clearly see  
359 that women receive more antibiotics in primary care, which is at odds with higher male  
360 resistance rates in our previous research in BSIs across Europe<sup>25</sup> and available UK  
361 data<sup>33</sup>. Such patterns point to unexplained complexity in the pathways to resistance  
362 acquisition and potential intervention targets such as increased age or even sex-based  
363 prescribing recommendations. Untangling the link from ABU to AMR will require further  
364 age and sex disaggregated data but also information on other covariables such as  
365 patient ethnicity, deprivation level and co-morbidities<sup>18,57</sup>.

366

367 Whilst the data used here is unparalleled in its detail and completeness, more patient  
368 data was available at later time points (a total of 3.3% of prescriptions were excluded),

369 leading us to focus on the more complete 2023 data and we had to use sensitivity  
370 analyses to explore the hidden low numbers of prescriptions. Our data improves upon  
371 previous studies which have banded either patient age (in 10+ age bands), not  
372 considered disaggregation by sex or only focused on a subset of patient diagnoses<sup>7-9</sup>.  
373 Moreover, much work in the UK is not all national data, using either only a subset of GPs  
374<sup>8,9,57,58</sup> which although designed to be representative, may miss subtle geographical  
375 variation or incomplete market coverage (e.g. IQVIA has 89% market coverage in the UK  
376<sup>50</sup>). However, here we only had access to prescription data, with no measure of the  
377 propensity to take the prescribed medicine and whether this varies by age, sex, time or  
378 drug, no linked diagnosis or reason for prescribing, and only “Items”, rather than a more  
379 specific quantification, such as daily defined doses (DDDs) or grams<sup>59</sup>. This is  
380 important as dose and duration of exposure is potentially relevant to the development  
381 of resistance<sup>60-62</sup>.

382

383 The generalisability of this analysis to other locations is likely low (except in related  
384 geographies e.g. Wales, Scotland etc.), as the results may not be applicable to  
385 countries with different prescribing guidelines and healthcare systems (e.g. US  
386 insurance-based prescribing<sup>63</sup>, or over-the-counter availability in LMICs<sup>64</sup>). However,  
387 many of the underlying infection syndromes and behaviour patterns may exist and  
388 hence our findings add to the increasing evidence that we need disaggregated data by  
389 age and sex to optimally intervene against AMR.

390

391 Our analysis highlights the possibilities of using FOI requests in research. Future  
392 researchers could request additional UK data, e.g. at the GP level over larger time

393 periods to avoid the issue of small numbers, as well as exploring requests for further  
394 (ideally linked) data that could help answer questions on health inequality such as  
395 socio-economic status and secondary health care infrastructure <sup>65</sup>.

396

397 Overall, by showing wide antibiotic prescription variation across age and sex this  
398 research has demonstrated the need for a nuanced approach when exploring and  
399 understanding trends in ABU. Understanding how this affects the global public health  
400 problem that is AMR can only be done with matched age and sex disaggregated AMR  
401 data otherwise the impact of ABU targets, ageing populations and future interventions  
402 will be very hard to determine.

403

404

#### 405 **Acknowledgments**

406 We would like to thank Yasmin Gant for supporting our understanding of reasons for  
407 antibiotic prescriptions, and Stephanie Evans for providing feedback on the manuscript.

408

#### 409 **Funding**

410 GMK and NRW were supported by the Medical Research Council UK,  
411 <https://www.ukri.org/opportunity/career-development-award/> (MR/W026643/1). The  
412 funders had no role in study design, data collection and analysis, decision to publish, or  
413 preparation of the manuscript

414

#### 415 **Transparency declarations**

416 No conflicts to declare.

## 417 **References**

418

419 1. WHO. Indicator Metadata Registry Details. [https://www.who.int/data/gho/indicator-](https://www.who.int/data/gho/indicator-metadata-registry/imr-details/5767)  
420 metadata-registry/imr-details/5767.

421 2. WHO. AWaRe. <https://adoptaware.org/> (2021).

422 3. Sharland, M. *et al.* The WHO AWaRe Antibiotic Book: providing guidance on optimal  
423 use and informing policy. *Lancet Infect. Dis.* **22**, 1528–1530 (2022).

424 4. Mendelson, M. *et al.* Ensuring progress on sustainable access to effective  
425 antibiotics at the 2024 UN General Assembly: a target-based approach. *The Lancet*  
426 **403**, 2551–2564 (2024).

427 5. NHS England. Community pharmacy quality scheme 2020-22: findings and  
428 recommendations from the antimicrobial stewardship initiatives.  
429 [https://www.england.nhs.uk/long-read/community-pharmacy-quality-scheme-](https://www.england.nhs.uk/long-read/community-pharmacy-quality-scheme-2020-22-findings-and-recommendations-from-the-antimicrobial-stewardship-initiatives/)  
430 2020-22-findings-and-recommendations-from-the-antimicrobial-stewardship-  
431 initiatives/ (2023).

432 6. Sijbom, M., Büchner, F. L., Saadah, N. H., Numans, M. E. & De Boer, M. G. J. Trends in  
433 antibiotic selection pressure generated in primary care and their association with  
434 sentinel antimicrobial resistance patterns in Europe. *J. Antimicrob. Chemother.* **78**,  
435 1245–1252 (2023).

436 7. Schröder, W. *et al.* Gender differences in antibiotic prescribing in the community: a  
437 systematic review and meta-analysis. *J. Antimicrob. Chemother.* **71**, 1800–1806  
438 (2016).



- 439 8. Smith, D. R. M., Dolk, F. C. K., Smieszek, T., Robotham, J. V. & Pouwels, K. B.  
440 Understanding the gender gap in antibiotic prescribing: a cross-sectional analysis of  
441 English primary care. *BMJ Open* **8**, e020203 (2018).
- 442 9. Majeed, A. & Moser, K. Age- and sex-specific antibiotic prescribing patterns in  
443 general practice in England and Wales in 1996. *Br. J. Gen. Pract.* **49**, 735–736 (1999).
- 444 10. Hayward, G. N., Fisher, R. F. R., Spence, G. T. & Lasserson, D. S. Increase in  
445 antibiotic prescriptions in out-of-hours primary care in contrast to in-hours primary  
446 care prescriptions: service evaluation in a population of 600 000 patients. *J.*  
447 *Antimicrob. Chemother.* **71**, 2612–2619 (2016).
- 448 11. Dolk, F. C. K., Pouwels, K. B., Smith, D. R. M., Robotham, J. V. & Smieszek, T.  
449 Antibiotics in primary care in England: which antibiotics are prescribed and for  
450 which conditions? *J. Antimicrob. Chemother.* **73**, ii2–ii10 (2018).
- 451 12. Dias, S. P., Brouwer, M. C. & van de Beek, D. Sex and Gender Differences in Bacterial  
452 Infections. *Infect. Immun.* **90**, e0028322 (2022).
- 453 13. Foxman, B. The epidemiology of urinary tract infection. *Nat. Rev. Urol.* **7**, 653–660  
454 (2010).
- 455 14. Mor, A. *et al.* Antibiotic use varies substantially among adults: a cross-national  
456 study from five European Countries in the ARITMO project. *Infection* **43**, 453–472  
457 (2015).
- 458 15. European Centre for Disease Prevention and Control. *Antimicrobial Consumption in*  
459 *the EU/EEA (ESAC-Net) - Annual Epidemiological Report for 2021.*  
460 [https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-](https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-consumption-europe-2021)  
461 [consumption-europe-2021](https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-consumption-europe-2021) (2022).

- 462 16. Browne, A. J. *et al.* Global antibiotic consumption and usage in humans, 2000–18: a  
463 spatial modelling study. *Lancet Planet. Health* **5**, e893–e904 (2021).
- 464 17. Motta, M., Wilcock, M. & Heald, A. Using defined daily doses to review antibiotic  
465 prescribing. *Prescriber* **32**, 19–25 (2021).
- 466 18. Hope, E. C. *et al.* Identifying English Practices that Are High Antibiotic Prescribers  
467 Accounting for Comorbidities and Other Legitimate Medical Reasons for Variation.  
468 *EClinicalMedicine* **6**, 36–41 (2018).
- 469 19. Lloyd, D. C., Harris, C. M. & Roberts, D. J. Specific therapeutic group age-sex related  
470 prescribing units (STAR-PU): weightings for analysing general practices' prescribing  
471 in England. *BMJ* **311**, 991–994 (1995).
- 472 20. Krishnakumar, J. & Tsopra, R. What rationale do GPs use to choose a particular  
473 antibiotic for a specific clinical situation? *BMC Fam. Pract.* **20**, 178 (2019).
- 474 21. McDermott, D. Antimicrobial Prescribing Guidance - NICE & PHE Update. *NECS*  
475 *Medicines Optimisation* [https://medicines.necsu.nhs.uk/antimicrobial-prescribing-](https://medicines.necsu.nhs.uk/antimicrobial-prescribing-guidance-nice-phe-update/)  
476 [guidance-nice-phe-update/](https://medicines.necsu.nhs.uk/antimicrobial-prescribing-guidance-nice-phe-update/) (2018).
- 477 22. van Heuvel, L., Paget, J., Dückers, M. & Caini, S. The impact of influenza and  
478 pneumococcal vaccination on antibiotic use: an updated systematic review and  
479 meta-analysis. *Antimicrob. Resist. Infect. Control* **12**, 70 (2023).
- 480 23. Barchitta, M., Maugeri, A., Vinci, R. & Agodi, A. The Inverse Relationship between  
481 Influenza Vaccination and Antimicrobial Resistance: An Ecological Analysis of  
482 Italian Data. *Vaccines* **10**, 554 (2022).
- 483 24. Tadesse, B. T. *et al.* Vaccination to Reduce Antimicrobial Resistance Burden—Data  
484 Gaps and Future Research. *Clin. Infect. Dis.* **77**, S597–S607 (2023).

- 485 25. Waterlow, N. R., Cooper, B. S., Robotham, J. V. & Knight, G. M. Antimicrobial  
486 resistance prevalence in bloodstream infection in 29 European countries by age and  
487 sex: An observational study. *PLOS Med.* **21**, e1004301 (2024).
- 488 26. NHSBSA. FOI-01671 - Open Data Portal BETA.  
489 <https://opendata.nhsbsa.net/dataset/foi-01671> (2024).
- 490 27. Open Prescribing. BNF 5.1: Antibacterial drugs | OpenPrescribing.  
491 <https://openprescribing.net/bnf/0501/> (2024).
- 492 28. ONS. Estimates of the population for the UK, England, Wales, Scotland, and  
493 Northern Ireland - Office for National Statistics.  
494 [https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/  
495 populationestimates/datasets/populationestimatesforukenglandandwalesscotland  
496 andnorthernireland](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland) (2024).
- 497 29. ONS. Health geographies population estimates (Accredited official statistics) -  
498 Office for National Statistics.  
499 [https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/  
500 populationestimates/datasets/clinicalcommissioninggroupmidyearpopulationesti  
501 mates](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/clinicalcommissioninggroupmidyearpopulationestimates) (2024).
- 502 30. WHO. AWaRe classification of antibiotics for evaluation and monitoring of use,  
503 2023. <https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04>  
504 (2023).
- 505 31. Vaccine uptake guidance and the latest coverage data. *GOV.UK*  
506 <https://www.gov.uk/government/collections/vaccine-uptake> (2024).
- 507 32. NICE. Amoxicillin | Drugs | BNF content published by NICE.  
508 <https://bnf.nice.org.uk/drugs/amoxicillin/> (2024).

- 509 33. MRSA, MSSA and Gram-negative bacteraemia and CDI: annual report. *GOV.UK*  
510 [https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-](https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary)  
511 [and-c-difficile-infection-annual-epidemiological-commentary](https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary) (2024).
- 512 34. R Core Team. R: A language and environment for statistical computing. R  
513 Foundation for Statistical Computing, Vienna, Austria. (2018).
- 514 35. Gilchrist, K. Antibiotics prices surge in UK amid Strep A outbreak, leaving drugstores  
515 ‘footing the bill’. *CNBC* [https://www.cnbc.com/2022/12/13/strep-a-antibiotics-](https://www.cnbc.com/2022/12/13/strep-a-antibiotics-prices-shortages-hit-drugstores-amid-uk-outbreak.html)  
516 [prices-shortages-hit-drugstores-amid-uk-outbreak.html](https://www.cnbc.com/2022/12/13/strep-a-antibiotics-prices-shortages-hit-drugstores-amid-uk-outbreak.html) (2022).
- 517 36. Lymecline | Drugs | BNF content published by NICE.  
518 <https://bnf.nice.org.uk/drugs/lymecycline/> (2024).
- 519 37. Colistimethate sodium | Drugs | BNF content published by NICE.  
520 <https://bnf.nice.org.uk/drugs/colistimethate-sodium/> (2024).
- 521 38. NHS. Inhaled Therapy for Adults and Children with Cystic Fibrosis.  
522 [https://www.england.nhs.uk/wp-content/uploads/2018/07/Inhaled-therapy-for-](https://www.england.nhs.uk/wp-content/uploads/2018/07/Inhaled-therapy-for-adults-and-children-with-cystic-fibrosis.pdf)  
523 [adults-and-children-with-cystic-fibrosis.pdf](https://www.england.nhs.uk/wp-content/uploads/2018/07/Inhaled-therapy-for-adults-and-children-with-cystic-fibrosis.pdf) (2024).
- 524 39. NICE. Colistimethate sodium and tobramycin dry powders for inhalation for treating  
525 pseudomonas lung infection in cystic fibrosis | Guidance | NICE.  
526 <https://www.nice.org.uk/guidance/ta276/chapter/2-Clinical-need-and-practice>  
527 (2013).
- 528 40. Bagger, K., Nielsen, A. B. S., Siersma, V. & Bjerrum, L. Inappropriate antibiotic  
529 prescribing and demand for antibiotics in patients with upper respiratory tract  
530 infections is hardly different in female versus male patients as seen in primary care.  
531 *Eur. J. Gen. Pract.* **21**, 118–123 (2015).

- 532 41. Briscoe, M. E. Why do people go to the doctor? Sex differences in the correlates of  
533 GP consultation. *Soc. Sci. Med.* 1982 **25**, 507–513 (1987).
- 534 42. Wang, Y., Hunt, K., Nazareth, I., Freemantle, N. & Petersen, I. Do men consult less  
535 than women? An analysis of routinely collected UK general practice data. *BMJ Open*  
536 **3**, e003320 (2013).
- 537 43. Harvey, E. J., De Brún, C., Casale, E., Finistrella, V. & Ashiru-Oredope, D. Influence of  
538 factors commonly known to be associated with health inequalities on antibiotic use  
539 in high-income countries: a systematic scoping review. *J. Antimicrob. Chemother.*  
540 **78**, 861–870 (2023).
- 541 44. Smith, A. M. & McCullers, J. A. Secondary Bacterial Infections in Influenza Virus  
542 Infection Pathogenesis. *Influenza Pathog. Control - Vol. I* **385**, 327–356 (2014).
- 543 45. Joseph, C., Togawa, Y. & Shindo, N. Bacterial and viral infections associated with  
544 influenza. *Influenza Other Respir. Viruses* **7**, 105–113 (2013).
- 545 46. Feinmann, J. Analysis reveals global post-covid surge in infectious diseases. *BMJ*  
546 **385**, q1348 (2024).
- 547 47. Zhu, N. *et al.* Investigating the impact of COVID-19 on primary care antibiotic  
548 prescribing in North West London across two epidemic waves. *Clin. Microbiol.*  
549 *Infect.* **27**, 762–768 (2021).
- 550 48. Rezel-Potts, E., L'Esperance, V. & Gulliford, M. C. Antimicrobial stewardship in the  
551 UK during the COVID-19 pandemic: a population-based cohort study and  
552 interrupted time-series analysis. *Br. J. Gen. Pract.* **71**, e331–e338 (2021).
- 553 49. STAR-PUs - should we still be using them? | Bennett Institute for Applied Data  
554 Science. [https://www.bennett.ox.ac.uk/blog/2024/02/star-pus-should-we-still-be-](https://www.bennett.ox.ac.uk/blog/2024/02/star-pus-should-we-still-be-using-them/)  
555 [using-them/](https://www.bennett.ox.ac.uk/blog/2024/02/star-pus-should-we-still-be-using-them/) (2024).

- 556 50. Simmons, B. *et al.* Progress towards antibiotic use targets in eight high-income  
557 countries. *Bull. World Health Organ.* **99**, 550–561 (2021).
- 558 51. Bou-Antoun, S. *et al.* Age-related decline in antibiotic prescribing for uncomplicated  
559 respiratory tract infections in primary care in England following the introduction of a  
560 national financial incentive (the Quality Premium) for health commissioners to  
561 reduce use of antibiotics in the community: an interrupted time series analysis. *J.*  
562 *Antimicrob. Chemother.* **73**, (2018).
- 563 52. Balinskaite, V., Ap, J., A, H. & P, A. The Impact of a National Antimicrobial  
564 Stewardship Program on Antibiotic Prescribing in Primary Care: An Interrupted Time  
565 Series Analysis. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **69**, (2019).
- 566 53. Sexually transmitted infections (STIs): annual data. *GOV.UK*  
567 [https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-](https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables)  
568 [annual-data-tables](https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables) (2024).
- 569 54. Baguelin, M. *et al.* Assessing Optimal Target Populations for Influenza Vaccination  
570 Programmes: An Evidence Synthesis and Modelling Study. *PLoS Med.* **10**, (2013).
- 571 55. Schmidt-Ott, R. *et al.* Assessing direct and indirect effects of pediatric influenza  
572 vaccination in Germany by individual-based simulations. *Hum. Vaccines*  
573 *Immunother.* **16**, 836–845 (2019).
- 574 56. NHS England. Healthcare associated infections.  
575 <https://www.england.nhs.uk/patient-safety/healthcare-associated-infections/>  
576 (2024).
- 577 57. Shallcross, L., Beckley, N., Rait, G., Hayward, A. & Petersen, I. Antibiotic prescribing  
578 frequency amongst patients in primary care: a cohort study using electronic health  
579 records. *J. Antimicrob. Chemother.* **72**, 1818–1824 (2017).

- 580 58. Palin, V. *et al.* Antibiotic prescribing for common infections in UK general practice:  
581 variability and drivers. *J. Antimicrob. Chemother.* **74**, 2440–2450 (2019).
- 582 59. Ways for prescribing to be measured. *The Pharmaceutical Journal*  
583 [https://pharmaceutical-journal.com/article/ld/ways-for-prescribing-to-be-](https://pharmaceutical-journal.com/article/ld/ways-for-prescribing-to-be-measured)  
584 measured (2004).
- 585 60. Roberts, J. A., Kruger, P., Paterson, D. L. & Lipman, J. Antibiotic resistance--what's  
586 dosing got to do with it? *Crit. Care Med.* **36**, 2433–2440 (2008).
- 587 61. Teshome, B. F., Vouri, S. M., Hampton, N., Kollef, M. H. & Micek, S. T. Duration of  
588 Exposure to Antipseudomonal  $\beta$ -Lactam Antibiotics in the Critically Ill and  
589 Development of New Resistance. *Pharmacotherapy* **39**, 261–270 (2019).
- 590 62. Day, T. & Read, A. F. Does High-Dose Antimicrobial Chemotherapy Prevent the  
591 Evolution of Resistance? *PLoS Comput. Biol.* **12**, e1004689 (2016).
- 592 63. Olesen, S. W. *et al.* The distribution of antibiotic use and its association with  
593 antibiotic resistance. *eLife* **7**, (2018).
- 594 64. Kanan, M. *et al.* Empowering Low- and Middle-Income Countries to Combat AMR by  
595 Minimal Use of Antibiotics: A Way Forward. *Antibiotics* **12**, 1504 (2023).
- 596 65. The Kings fund. Health inequalities in a nutshell. *The King's Fund*  
597 [https://www.kingsfund.org.uk/insight-and-analysis/data-and-charts/health-](https://www.kingsfund.org.uk/insight-and-analysis/data-and-charts/health-inequalities-nutshell)  
598 inequalities-nutshell (2024).
- 599